This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pollick, C. Articles by Popp, R. L. Search for Related Content PubMed PubMed Citation Articles by Pollick, C. Articles by Popp, R. L.

Circulation, Vol 66, 447-453, Copyright © 1982 by American Heart Association

ARTICLES

The cardiac effects of d- and l-disopyramide in normal subjects: a noninvasive study

C Pollick, KM Giacomini, TF Blaschke, WL Nelson, K Turner-Tamiyasu, V Briskin and RL Popp

Commercially available disopyramide is a racemic mixture of equal parts of dextrorotatory (d-) and levorotatory (l-) optical isomers. We studied the cardiac effects of i.v. administration of each isomer and the racemic mixture (dl-) in six normal males by digitized echocardiography, systolic time intervals and ECG. Both isomers and the racemic mixture produced equally marked dose-dependent negative inotropic effects (28.1 +/- 11.8% mean maximal reduction in fractional shortening of left ventricular dimension) and diastolic effects (28.6 +/- 24.1% mean maximal reduction in peak left ventricular filling rate). However, only the d-isomer prolonged QTc duration (by 13.6 +/- 5.2% at maximum, p less than 0.001 vs l-isomer). We conclude that disopyramide, in the doses used, produces marked adverse effects on left ventricle systolic and diastolic function in normal subjects independent of optical rotation. The production of these effects by the l-isomer without affecting QTc duration suggests different subcellular mechanisms for the myocardial depressant effects and some of the electrophysiologic effects of disopyramide.

This article has been cited by other articles:

				M. V. Sherrid, I. Barac, W. J. McKenna, P. M. Elliott, S. Dickie, L. Chojnowska, S. Casey, and B. J. Maron Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1251 - 1258. [Abstract] [Full Text] [PDF]

				M. Hamada, Y. Shigematsu, S. Ikeda, Y. Hara, H. Okayama, K. Kodama, T. Ochi, and K. Hiwada Class Ia Antiarrhythmic Drug Cibenzoline : A New Approach to the Medical Treatment of Hypertrophic Obstructive Cardiomyopathy Circulation, September 2, 1997; 96(5): 1520 - 1524. [Abstract] [Full Text]

				P. L. McCollam and J. L. Bauman New Concepts in Antiarrhythmic Drug Monitoring Journal of Pharmacy Practice, January 1, 1989; 2(6): 393 - 402. [PDF]